New drug trial aims to stop fractures in kids with brittle bones
NCT ID NCT06636071
Summary
This study is testing whether a drug called setrusumab can reduce the number of broken bones in Japanese children with osteogenesis imperfecta (OI), also known as brittle bone disease. Six children with specific types of OI will receive the drug for up to two years, with the option to continue. The main goal is to see if the treatment lowers the yearly rate of fractures, including spine fractures.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOGENESIS IMPERFECTA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Keio University Hospital
Tokyo, Japan
-
Osaka Metropolitan University Hospital
Osaka, Japan
-
Osaka University Hospital
Osaka, Japan
Conditions
Explore the condition pages connected to this study.